Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Barbour AM, Rockich K, Cimino E, Zhou G, Leonetti-Whalen C, Chen X, Yeleswaram S, Epstein N, Punwani N. Barbour AM, et al. Among authors: yeleswaram s. J Clin Pharmacol. 2021 Jul;61(7):954-960. doi: 10.1002/jcph.1814. Epub 2021 Jan 28. J Clin Pharmacol. 2021. PMID: 33434286
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue TY, Yeleswaram S. Shilling AD, et al. Among authors: yeleswaram s. Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787. Epub 2010 Aug 10. Drug Metab Dispos. 2010. PMID: 20699411 Clinical Trial.
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S. Shi JG, et al. Among authors: yeleswaram s. J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20. J Clin Pharmacol. 2012. PMID: 21602517 Clinical Trial.
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P, Hertel D, Haley P, Lo Y, Waeltz P, Rodgers J, Shepard S, Vaddi K, Yeleswaram S, Levy R, Williams W, Gottlieb AB. Punwani N, et al. Among authors: yeleswaram s. Br J Dermatol. 2015 Oct;173(4):989-97. doi: 10.1111/bjd.13994. Epub 2015 Oct 14. Br J Dermatol. 2015. PMID: 26123031 Clinical Trial.
78 results